The number of people diagnosed with asbestos caused diseases in the U.S. continues to increase. Experts believe 60,000 mesothelioma deaths will occur between 2010 and 2030.

Work related injuries harm up to 14 million people annually, with harms including traumatic brain injuries, spinal injuries, amputations, burns, and electrocutions. Around 20,000 to 60,000 workers die each year from accidents, toxins, and violence at their jobs.

Millions of consumers and workers are injured each year because of defective products. Defects can occur when a product is designed poorly, when a product is manufactured in a manner that differs from the intended design, or when the product does not contain proper warnings or instructions. Defects can occur in automobiles, pharmaceuticals, medical devices, construction equipment, toys, and other goods.

Between 1.5 and 2 million elderly reside in nursing home facilities, with studies revealing that 44% have suffered some form of abuse. Many believe the actual number of residents suffering abuse is much higher. Neglect and abuse may result in serious emotional, physical, and financial harm

Paul & Hanley’s legal team has produced some of the most notable verdicts and highest settlements in the United States. Over 500 of our clients have each obtained in excess of 1 million dollars. Over 250 have recovered multi-million dollar recoveries.

Pleural, Peritoneal, and Tunica Vaginalis Mesothelioma Clinical Trial Using AZD2171

AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Last Modified: 4/6/2009     First Published: 3/24/2006  

Alternate Title

Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Biomarker/Laboratory analysis, Treatment Active 18 and over NCI UCCRC-14203B
NCI-7103, 7103, NCT00309946

Trial Description

Purpose:

AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

This phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.

Eligibility:

Eligibility criteria include the following:

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive ADZ2171 by mouth once a day. Treatment may continue for as long as benefit is shown. Blood will be collected periodically for laboratory studies.

After finishing treatment, patients will be evaluated for up to 8 weeks.

Important:

For more details about this trial, refer to the Health Professional version 6 of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site 7.

Trial Contact Information

Trial Lead Organizations

University of Chicago Cancer Research Center

Hedy Kindler, MD, Principal investigator
Ph: 773-702-0360; 888-824-0200

Trial Sites

U.S.A.
California
  Beverly Hills
 
 
 
  Tower Cancer Research Foundation
 
  Philomena McAndrew, MD
Ph:  310-888-8680
   
 
  Duarte
 
  City of Hope Comprehensive Cancer Center
 
  Clinical Trials Office - City of Hope Comprehensive Cancer Center
Ph:  800-826-4673
   
  Email: becomingapatient@coh.org
 
  Los Angeles
 
  USC/Norris Comprehensive Cancer Center and Hospital
 
  Clinical Trials Office - USC/Norris Comprehensive Cancer Center and Hospital
Ph:  323-865-0451
   
 
  Martinez
 
  Contra Costa Regional Medical Center
 
  Sharon Hiner, MD
Ph:  925-370-5114
  800-232-4636
  Email: shiner@hsd.co.contra-costa.ca.us
 
  Pasadena
 
  City of Hope Medical Group
 
  Mark McNamara, MD
Ph:  626-396-2900
   
  Email: mmcnamara@ccsmg.com
 
  Sacramento
 
  University of California Davis Cancer Center
 
  Clinical Trials Office - University of California Davis Cancer Center
Ph:  916-734-3089
   
 
Illinois
  Chicago
 
 
  University of Chicago Cancer Research Center
 
  Clinical Trials Office - University of Chicago Cancer Research Center
Ph:  773-834-7424
   
 
  Decatur
 
  Decatur Memorial Hospital Cancer Care Institute
 
  Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute
Ph:  217-876-6601
   
 
  Evanston
 
  Evanston Hospital
 
  Clinical Trials Office - Evanston Hospital
Ph:  847-570-1381
   
 
  Harvey
 
  Ingalls Cancer Care Center at Ingalls Memorial Hospital
 
  Clinical Trials Office - Ingalls Cancer Care Center at Ingalls Memorial Hospital
Ph:  708-915-6747
   
 
  Maywood
 
  Cardinal Bernardin Cancer Center at Loyola University Medical Center
 
  Clinical Trials Office - Cardinal Bernardin Cancer Center
Ph:  708-226-4357
   
 
  Peoria
 
  Oncology Hematology Associates of Central Illinois, PC - Peoria
 
  Sachdev Thomas, MD
Ph:  309-243-1000
   
  Email: sthomas@ohaci.com
 
  Springfield
 
  Central Illinois Hematology Oncology Center
 
  Edem Agamah, MD, MS
Ph:  217-525-2500
   
  Email: ihdn@aol.com
 
Indiana
  Fort Wayne
 
 
  Fort Wayne Medical Oncology and Hematology
 
  David Sciortino, MD
Ph:  260-484-8830
  800-852-2333
 
  South Bend
 
  CCOP - Northern Indiana CR Consortium
 
  David Taber, MD
Ph:  574-647-3353
  800-284-7370
 
Michigan
  Saint Joseph
 
 
  Oncology Care Associates, PLLC
 
  Eric Lester, MD
Ph:  269-985-0029
   
 
Pennsylvania
  Hershey
 
 
  Penn State Cancer Institute at Milton S. Hershey Medical Center
 
  Clinical Trials Office - Penn State Cancer Institute at Milton S. Hershey Medical Center
Ph:  717-531-3779
   
  Email: CTO@hmc.psu.edu
 
Wisconsin
  Milwaukee
 
 
  Medical College of Wisconsin Cancer Center
 
  Clinical Trials Office - Medical College of Wisconsin Cancer Center
Ph:  414-805-4380
   
 
Canada
Ontario
  Toronto
 
 
 
  Princess Margaret Hospital
 
  Natasha Leighl, MD, FRCPC
Ph:  416-946-2399
   
 

Registry Information
Official Title   Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma
Trial Start Date   2005-12-05
Trial Completion Date   2006-10-01 (estimated)
Registered in ClinicalTrials.gov   NCT00309946 8
Date Submitted to PDQ   2005-12-09
Information Last Verified   2007-06-03
NCI Grant/Contract Number   CM17102, CA14599


Glossary Terms

AZD2171

A substance being studied in the treatment of some types of cancer. AZD2171 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called cediranib and Recentin.

blood

A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes.

brain metastasis (...meh-TAS-tuh-sis)

Cancer that has spread from the original (primary) tumor to the brain.

cell (sel)

The individual unit that makes up the tissues of the body. All living things are made up of one or more cells.

chemotherapy (KEE-moh-THAYR-uh-pee)

Treatment with drugs that kill cancer cells.

eligibility criteria (EH-lih-jih-BIH-lih-tee kry-TEER-ee-uh)

In clinical trials, requirements that must be met for an individual to be included in a study. These requirements help make sure that patients in a trial are similar to each other in terms of specific factors such as age, type and stage of cancer, general health, and previous treatment. When all participants meet the same eligibility criteria, it gives researchers greater confidence that results of the study are caused by the intervention being tested and not by other factors.

enzyme (EN-zime)

A protein that speeds up chemical reactions in the body.

malignant mesothelioma (muh-LIG-nunt MEH-zoh-THEE-lee-OH-muh)

A rare type of cancer in which malignant cells are found in the lining of the chest or abdomen. Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma.

measurable disease

A tumor that can be accurately measured in size. This information can be used to judge response to treatment.

phase II trial

A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer.

radiation therapy (RAY-dee-AY-shun THAYR-uh-pee)

The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that travels in the blood to tissues throughout the body. Also called irradiation and radiotherapy.

surgery (SER-juh-ree)

A procedure to remove or repair a part of the body or to find out whether disease is present. An operation.

tumor (TOO-mer)

An abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Tumors may be benign (not cancer), or malignant (cancer). Also called neoplasm.

Table of Links

1 http://www.cancer.gov/clinicaltrials/learning
2 http://www.cancer.gov/cancertopics/factsheet/Information/clinical-trials
3 http://www.cancer.gov/clinicaltrials/learning/questions-to-ask-about-participat
ing
4 http://www.nlm.nih.gov/medlineplus/druginformation.html
5 http://www.cancer.gov/clinicaltrials/UCCRC-14203B#EntryCriteria_CDR0000463521
6 http://www.cancer.gov/clinicaltrials/UCCRC-14203B
7 http://cancer.gov/clinicaltrials
8 http://clinicaltrials.gov/ct/show/NCT00309946